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Abstract: One of the characteristics of Alzheimer´s disease (AD) is an increased amyloid load and
an enhanced level of reactive oxidative species (ROS). Vitamin E has known beneficial neuroprotective
effects, and previously, some studies suggested that vitamin E is associated with a reduced risk of AD
due to its antioxidative properties. However, epidemiological studies and nutritional approaches of
vitamin E treatment are controversial. Here, we investigate the effect of α-tocotrienol, which belongs
to the group of vitamin E, on AD-relevant processes in neuronal cell lines. In line with the literature,
α-tocotrienol reduced the ROS level in SH-SY5Y cells. In the presence of tocotrienols, cholesterol
and cholesterol esters, which have been shown to be risk factors in AD, were decreased. Besides the
unambiguous positive effects of tocotrienol, amyloid-β (Aβ) levels were increased accompanied by
an increase in the activity of enzymes responsible for Aβ production. Proteins and gene expression of
the secretases and their components remained unchanged, whereas tocotrienol accelerates enzyme
activity in cell-free assays. Besides enhanced Aβ production, tocotrienols inhibited Aβ degradation
in neuro 2a (N2a)-cells. Our results might help to understand the controversial findings of vitamin E
studies and demonstrate that besides the known positive neuroprotective properties, tocotrienols
also have negative characteristics with respect to AD.
Keywords: tocotrienol; vitamin E; Alzheimer´s disease; amyloid-β; tocopherol; Aβ degradation;
β-secretase; γ-secretase
Int. J. Mol. Sci. 2016, 17, 1809; doi:10.3390/ijms17111809 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2016, 17, 1809 2 of 18
1. Introduction
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder and the most common
cause of dementia in the elderly, pathologically characterized by neuritic plaques and intracellular
neurofibrillary tangles (NFTs). Neuritic plaques are composed of aggregated amyloid-β (Aβ) peptides,
generated by sequential proteolytic processing of the amyloid precursor protein (APP) by the
aspartyl-proteases β- and γ-secretase, whereas hyperphosphorylated microtubule-associated protein
tau is the main component of NFTs [1–3]. Although extracellular neuritic plaques consisting of
aggregated Aβ peptides are the undisputable characteristic feature of AD, increasing evidence suggests
that the oligomeric form of Aβ with up to 50 Aβ subunits represents the most toxic species of Aβ [4,5].
Several mechanisms of Aβ toxicity play a crucial role in AD, including cholinergic dysfunction,
disruption of calcium homeostasis, inflammation, increased oxidative stress and mitochondrial
dysfunction, finally resulting in neuronal/synaptic dysfunction and neuronal loss [6–10]. So far,
increased age seems to be the most significant risk factor contributing to sporadic AD. Furthermore,
carrying one or two copies of the apolipoprotein E (Apo E) ε4 alleles, one of the main apolipoproteins
in the brain importing cholesterol into neurons via lipoprotein receptor-related protein, is a major risk
factor for late-onset sporadic AD [11]. Hypercholesterolemia has also been proposed to be a risk factor
in Alzheimer´s disease, especially for the amyloid pathology, which has been confirmed by several
longitudinal, population-based studies, demonstrating that cholesterol is associated with AD in later
lifespan [12]. Further studies support that cholesterol metabolism is linked to the susceptibility to AD.
Diet-induced hypercholesterolemia in a transgenic mouse model for AD increased total Aβ levels,
whereas cholesterol-lowering drugs reduced Aβ pathology in transgenic mice [13–15]. Rabbits fed
with a cholesterol-rich diet showed a two-fold increase in β-amyloid concentration in the hippocampal
formation [16]. Molecular and mechanistic evidence points towards a direct effect of cholesterol in
AD pathogenesis by enhancing β- and γ-secretase-mediated Aβ production [17–21]. Several clinical
trials associated statins, inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and, thus,
cholesterol de novo synthesis, with a diminished risk to AD [22–24], whereas other clinical studies
showed no differences [25–27]. However, cholesterol modulation might be an effective approach for
reducing the risk of developing AD.
Molecules of the vitamin E family have been shown to exert hypocholesterolemic properties [28–32].
Vitamin E mainly consists of two families of lipophilic compounds: tocopherols and tocotrienols.
Both families share a chromanol ring and an isoprenoid-derived side chain (Figure 1A). The side
chain is saturated in tocopherols and unsaturated in tocotrienols. The chromanol ring of tocopherols
and tocotrienols can be methylated at position C5 and C7 leading to α-, β-, γ- and δ-tocopherol or
tocotrienol. Vitamin E is an essential component of the human diet and was primarily recognized for its
antioxidant activity [33]. This micronutrient has already been proposed as a preventive agent in AD as
increased oxidative stress by free radicals plays a crucial role in AD pathogenesis [34–36]. Tocotrienols
also show a variety of neuroprotective activity, including anti-inflammatory activity [37–41]. However,
besides the undisputable protective effects of vitamin E molecules, it has recently been shown that
tocopherols increase the Aβ level [42]. However, so far, nothing is known about the amyloidogenic
potential of tocotrienol. Therefore, we analyzed in the present study the effect of tocotrienol on Aβ
generation and Aβ degradation.
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Figure 1. Effect of α-tocopherol and α-tocotrienol on cholesterol level. Error bars represent the 
standard deviation of the mean. Asterisks show the statistical significance calculated by post hoc 
ANOVA compared to the solvent control (*** p ≤ 0.001). (A) Skeletal formulas of α-tocopherol and 
α-tocotrienol. The red lines indicate the double bonds; (B,C) effect of α-tocopherol and α-tocotrienol 
in SH-SY5Y wildtype cells on esterified and unesterified (total) cholesterol (B) (α-tocopherol:  
91.2% ± 1.0%, p ≤ 0.001, n = 8; α-tocotrienol: 57.7% ± 0.6%, p ≤ 0.001, n = 8) and unesterified (free) 
cholesterol (C) (α-tocopherol: 93.4% ± 0.5%, p ≤ 0.001, n = 8; α-tocotrienol: 63.7% ± 0.7%, p ≤ 0.001,  
n = 8) compared to the solvent control. One hundred percent in the control cells equates 0.0211 µg 
total cholesterol/µg protein (B) and 0.0161 µg free cholesterol/µg protein (C). 
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2.1. Effect of α-Tocopherol and α-Tocotrienol on Cholesterol Level 
As described above, the vitamin E family consists of tocopherols and tocotrienols. α-tocopherol 
is the most abundant form among the tocopherols and mainly used in supplements; in accordance, 
α-tocotrienol is the most common form of the tocotrienols [43]. We therefore investigated the effect 
of both α-forms, which only differ in their chemical structure in the number of double bonds, on the 
cholesterol level. 
Vitamin E compounds have been shown to exert hypocholesterolemic activity by affecting the 
sterol regulatory element binding protein/SREBP cleavage activating protein (SREBP/SCAP) 
system, one of the main systems regulating cholesterol homeostasis [28,30,44–46]. High cholesterol 
levels are discussed to be a risk factor for AD [12]. Cellular cholesterol exists in two major forms:  
(1) unesterified (free) cholesterol that possess a free 3-β-OH at the steroid ring B; and (2) cholesteryl 
esters (esterified cholesterol). Cholesterol acyltransferase (ACAT) responsible for the conversion of 
free cholesterol to esterified cholesterol has been shown to be affected in AD [47]. In principle, 
vitamin E molecules could not only influence cholesterol de novo synthesis by affecting the 
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The red lines indicate the double bonds; (B,C) effect of α-tocopherol and α-tocotrienol in SH-SY5Y
wildtype cells on esterified and unesterified (total) cholesterol (B) (α-tocopherol: 91.2% ± 1.0%,
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2. Results
2.1. Effect of α-Tocopherol and α-Tocotrie ol on Cholesterol Level
As described above, the vitamin E family consists of tocopherols and tocotrienols. α-tocopherol
is the most abundant form among the tocopherols and mainly used in supplements; in accordance,
α-tocotrienol is the most common form of the tocotrienols [43]. We therefore investigated the effect
of both α-for s, which only differ in their chemical s ructure in the number of double bo ds, on the
chole terol l ve .
Vita in E c mpounds have been shown t exert hypocholesterolemic activity by affecting the
sterol regulatory element binding protein/SREBP cleavage activating protein (SREBP/SCAP) system,
one of the main systems regulating cholesterol homeostasis [28,30,44–46]. High cholesterol levels are
discussed to be a risk factor for AD [12]. Cellular cholesterol exists in two major forms: (1) unesterified
(free) cholesterol that possess a free 3-β-OH at the steroid ring B, instead of; and (2) cholesteryl esters
(esterified cholesterol). Cholesterol acyltransferase (ACAT) responsible for the conversion of free
cholesterol to esterified cholesterol has been shown to be affected in AD [47]. In principle, vitamin E
molecules could not only influence cholesterol de novo synthesis by affecting the SREBP/SCAP system,
but also alter cholesterol-esterase or cholesterol-ester synthase activity. Therefore, we determined in
the present study unesterified, as well as total cholesterol levels.
Int. J. Mol. Sci. 2016, 17, 1809 4 of 18
As the above-mentioned studies were performed in non-neuronal cell lines, we used human
neuroblastoma SH-SY5Y wildtype (wt) cells to determine the effect of α-tocopherol and α-tocotrienol
on non-esterified and total cellular cholesterol, including esterified cholesterol level. Cells were
maintained for three days in 1% fetal calf serum (FCS) in the presence of 10 µM α-tocopherol or
α-tocotrienol, followed by treatment for 48 h in 0.1% FCS, to further reduce external sterol sources.
Notably, we used a concentration of 10 µM, as it has been shown that tocopherol isomers occur
in the human brain in concentrations of 0.11–17.9 µM [48]. Cholesterol levels were determined
using an Amplex Red-based cholesterol assay, either in the absence of cholesterol-esterase for the
determination of free cholesterol (unesterified cholesterol) or in the presence of cholesterol-esterase for
the analysis of total cholesterol level (esterified and unesterified cholesterol). The α-tocopherol-treated
cells showed a slight, but significant reduction in total cholesterol to 91.2% and free cholesterol level to
93.4% compared to solvent-treated SH-SY5Y wt cells (α-tocopherol: total cholesterol: 91.2% ± 1.0%,
p ≤ 0.001; free cholesterol: 93.4% ± 0.5%, p ≤ 0.001) (Figure 1B,C). For α-tocotrienol, we found
a strong and significant reduction in total and free cholesterol level. In the presence of α-tocotrienol,
the total cholesterol level was decreased to 57.7% and the free cholesterol level to 63.7% (α-tocotrienol:
total cholesterol: 57.7% ± 0.6%, p ≤ 0.001; free cholesterol: 63.7% ± 0.7%, p ≤ 0.001). Remarkably,
compared to α-tocopherol, the reduction of total cholesterol and unesterified cholesterol level in
α-tocotrienol-treated cells is highly significant (Figure 1B,C).
2.2. Reactive Oxidative Species Are Reduced in the Presence of α-Tocopherol and α-Tocotrienol
Vitamin E is known for its antioxidant activity [33]. To analyze whether tocopherols and
tocotrienols exert different effects on the production of reactive oxidative species (ROS), we incubated
SH-SY5Y wt cells 24 h in FCS-reduced culture medium in the presence of 10 µM α-tocopherol
or α-tocotrienol. Notably, at these experimental conditions, α-tocopherol and α-tocotrienol
showed no significant changes in cytotoxicity compared to solvent-treated control cells (Figure S1).
2-[6-(4’-amino)phenoxy-3H-xanthen-3-on-9-yl]benzoic acid (aminophenyl fluorescein (APF)) was
used to selectively detect highly reactive oxygen species (hROS), including hypochlorite (–OCl) and
free hydroxyl radical (·OH) [49]. The generation of ROS was slightly, but not significantly reduced
to 88.3% in the presence of α-tocopherol (Figure 2A) compared to solvent-treated cells. A very
similar, but significant reduction to 84.9% was obtained for α-tocotrienol (α-tocopherol: 88.3% ± 3.6%,
p = 0.07; α-tocotrienol: 84.9% ± 2.6%, p = 0.012). The determination of ROS level, induced by using
hydrogen peroxide (H2O2), revealed a significant reduction to 91.6% for α-tocopherol (α-tocopherol:
91.6% ± 3.2%; p = 0.029) (Figure 2B). The α-tocotrienol-treated cells showed a reduction to 89.1%
for H2O2-induced ROS level (α-tocotrienol: 89.1% ± 2.3%, p = 0.006). Similar to the results for ROS
level detected by APF, we observed no significant differences in H2O2-induced ROS levels between
α-tocopherol and α-tocotrienol treatment (Figure 2A,B).
2.3. Effect of α-Tocotrienol on Aβ Generation and Aβ Degradation
In a previous study, we have shown that tocopherols increase the Aβ level [42]. The total
Aβ level depends on Aβ generation by proteolytic processing of APP and Aβ clearance by Aβ
degrading enzymes, like neprilysin or insulin-degrading enzyme (IDE) [50–54]. To analyze the effect
of α-tocotrienol on Aβ generation, we focused on the amyloidogenic pathway involving β- and
γ-secretase cleavage of APP (Figure 3A). β-site shedding of APP by BACE1 initiates the production
of Aβ peptides, generating soluble sAPPβ and a membrane-tethered C-terminal fragment called
βCTF or C99, which is further cleaved by the γ-secretase complex to release Aβ [2]. The influence
of α-tocotrienol on the total Aβ level was analyzed in SH-SY5Y cells stably transfected with human
APP695, an APP isoform mainly expressed in neurons [55]. The Aβ level was determined by using the
antibody W02, recognizing an epitope between amino acids 1–10 of the Aβ peptide, thus, detecting
the total Aβ level (Aβ1–X) including Aβ1–40 and Aβ1–42. α-tocotrienol significantly increased the
total Aβ level to 116.7% (116.7% ± 3.1%, p ≤ 0.001) (Figure 3B). An increase in the Aβ level to 116.7%
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might appear rather small; however, one has to take into consideration that AD has a long preclinical
phase and that a small increase in the Aβ level can result in an earlier disease onset [56].
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Figure 2. Effect of α-tocopherol and α-tocotrienol on oxidative stress. Reactive oxidative species
measured with aminophenyl fluorescein (APF) (A) (α-tocopherol: 88.3% ± 3.6%, p = 0.07, n = 16;
α-tocotrienol: 84.9% ± 2.6%, p = 0.012, n = 16) or induced reactive oxidative stress by hydrogen
peroxide incubation (B) (α-tocopherol: 91.6% ± 3.2%; p = 0.029, n = 10; α-tocotrienol: 89.1% ± 2.6%,
p = 0.006, n = 10) in the presence ofα-tocopherol andα-tocotrienol in SH-SY5Y wildtype cells. Statistical
significance as described for Figure 1 (* p ≤ 0.05, ** p ≤ 0.01 and n.s., not significant). In (A),
the oxidative stress is measured by APF detecting several reactive oxidative species with different
efficiency. Therefore, an absolute v lue of the ROS cannot be presented. However, w estimated
the concentration of ROS by using NaOCl. The determi ed amount of NaOCl has shown the same
APF-m diated fluor scence, which has been measured in the control cells. One hundred percent in the
control cells equates to 2.89 nM NaOCl; In (B), 100% is the equivalent of 0.95 µM H2O2.
To exclude unphysiologically-relevant effects by the use of APP overexpressing cells, we also
incubated SH-SY5Y wildtype (wt) cells in the presence of 10 µM α-tocotrienol or the solvent control.
For SH-SY5Y wt cells, we observed an even stronger increase in the Aβ level in the presence of
α-tocotrienol (146.7% ± 2.3%, p ≤ 0.001) (Figure 3C). The increased effect strength might be explained
by the fact that potential effects on Aβ degradation are less visible in a system where de novo synthesis
of Aβ is as high as in APP overexpressing cells.
To analyze whether α-tocotrienol directly affects secretase activities, we used post-nuclear
membrane fractions of SH-SY5Y wt cells and measured β- and γ-secretase activity. Therefore, purified
membranes were prepared from SH-SY5Y wt cells. After preparation, these purified membranes were
in vitro incubated in the presence or absence of α-tocotrienol, and β- and γ-secretase activity was
determined. As α-tocotrienol was added after the membranes were prepared, the observed effects on
secretase activities are independent of tocotrienol-m diated changes in gene xpression or cholesterol
level or other mechanisms, which are dependent on intact cells. We found th t α-tocotrienol directly
increased β-secretase activity to 116.3% (β-secretase activity: 116.3% ± 3.3%, p = 0.01) (Figure 3D).
Western blot analysis of the sAPPβ level in the conditioned medium of tocotrienol-treated SH-SY5Y
APP695 cells revealed an increased sAPPβ protein level to 136.8% (136.8%± 3.3%, p = 0.004) (Figure S2),
further underlining increased γ-secretase cleavage in the presence of tocotrienol. Similarly, we
observed a direct effect of α-tocotrienol on γ-secretase activity, which was elevated to 118.3% in the
presence of α-tocotrienol compared to solvent-treated control cells (γ-secretase activity: 118.3% ± 4.5%,
p = 0.02) (Figure 3E). To verify the direct effect on γ-secretase activity, we investigated SH-SY5Y cells
stably expressing C99. As the Aβ level in C99 transfected cells is only dependent on γ-secretase
cleavage, potential alterations in the Aβ level are caused by changes in γ-secretase processing [57].
In line with the observed increased γ-secretase activity (Figure 3E), the Aβ level was elevated to
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133.6% (133.6% ± 2.8%, p ≤ 0.001) in tocotrienol-incubated C99 transfected SH-SY5Y cells (Figure S3).
The direct effect of tocotrienol on secretase activities could be substantiated by increased β- and
γ-secretase activity in living SH-SY5Y wt cells in the presence of α-tocotrienol (β-secretase activity:
118.3% ± 4.6%, p = 0.001; γ-secretase activity: 132.6% ± 7.3%, p = 0.0003). Besides the direct effect
of α-tocotrienol on β- and γ-secretase activity, we analyzed whether indirect tocotrienol-mediated
mechanisms, like gene expression, might be involved in elevated amyloidogenic APP processing.
Quantitative real-time PCR analysis revealed no changes in gene transcription of β-secretase BACE1
(Figure S4). Gene expression of the γ-secretase components presenilin 1 (PSEN1) and presenilin 2
(PSEN2), nicastrin (NCSTN), presenilin-enhancer 2 (PSENEN) and anterior-pharynx-defective 1A
(APH1A) was also unchanged in the presence of α-tocotrienol (Figure S4). Only gene transcription
of the γ-secretase component APH1B was slightly, but significantly reduced to 85.2% (85.2% ± 3.4%,
p ≤ 0.001). In accordance with the unchanged gene transcription of BACE1 and nicastrin, the protein
level of BACE1 and nicastrin was unaltered (Figure S5), further indicating that α-tocotrienol exerts
its amyloidogenic potential by primarily directly affecting β- and γ-secretase. The overproduction
of Aβ peptides, as well as reduced Aβ clearance contribute to AD [54,58]. Therefore, we analyzed
whether α-tocotrienol affects Aβ degradation by incubating synthetic human Aβ40 in the presence of
α-tocotrienol or the solvent on living cells for six hours and quantifying the remaining human Aβ40 by
Western blot analysis. In order to avoid the detection of Aβ generated by the cells, we chose the mouse
neuroblastoma cell line neuro 2a (N2a) and the antibody W02, recognizing human, but not mouse
Aβ peptides, for this experiment (Figure 3F,G). In the presence of α-tocotrienol, Aβ degradation was
reduced to 82.1% (82.1% ± 3.7%, p = 0.003) (Figure 3F), indicating that α-tocotrienol decreases Aβ
degradation. Interestingly, in the presence of insulin, a competitive inhibitor of the IDE, one of the most
important enzymes in Aβ degradation, tocotrienol, had no effect on Aβ degradation (93.8% ± 2.3%,
p = 0.09) (Figure 3G). We therefore conclude that tocotrienol acts via a mechanism in Aβ degradation,
in which IDE plays an essential role.
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3. Discussion
Vitamin E is a natural phyto-compound and frequently used as a nutritional upplement.
Tocopherols are mainly found in vegetable oil, whereas the second family of vitamin E, the tocotrienols,
is sourced from cereal grains and palm oil [59]. Tocopherols and tocotrienols are discussed to be
important for successful aging, including cognitive performance [60]. Besides the well-known
antioxidative activity of vitamin E, molecules of the vitamin E family show neuroprotective,
anti-inflammatory and cholesterol-lowering properties [28,33,40,41], mechanisms that are also
important in the pathog nesis of AD [61]. Earl studie alr ady reported a hypocholest rolemic activity
of synthetic and natural tocotrienols [28,30]. fter the identification of the SREBP/SCAP system by
the laboratory of Brown and Goldstein [62,63], more recent studies showed that members of the
vitamin E family decrease the cellular cholesterol level by affecting the SREBP/SCAP system [44–46].
The SREBP/SCAP system is one of the main systems controlling the cellular cholesterol level.
Briefly, when the cholesterol level is low, SREBP-2 (sterol regulatory element binding protein 2),
which is tethered to the endoplasmic reticulum (ER) as a full-length protein, is escorted by SCAP
(SREBP-2 cleavage activating protein) to the Golgi apparatus, where SREBP-2 is cleaved by site-1- and
site-2-protease releasing the active N-terminal portion of SREBP-2, which migrates to the nucleus and
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upregulates genes involved in cholesterol synthesis and cholesterol uptake [62]. The resulting increased
cholesterol level promotes binding of SCAP to Insig (insulin-induced gene), retaining full-length
SREBP-2 in the ER. Song and DeBose-Boyd reported that δ-tocotrienol blocks processing of SREBP-2
and stimulates HMGCR degradation, whereas γ-tocotrienol enhances primarily HMGCR degradation
in SV589 cells, an immortalized line of human fibroblasts expressing the SV-40 large T-antigen [44].
α-tocotrienol and all tocopherols showed no measurable effect on reductase degradation or SREBP
processing [44]. However, α-tocopherol has also been reported to decrease activated nuclear SREBP-2
resulting in a reduction of the expression of 10 genes involved in cholesterol de novo synthesis [45].
In line with this study, we found significantly decreased cholesterol level in the presence ofα-tocopherol
in SH-SY5Y neuroblastoma cells: unesterified cholesterol was reduced to 93.4% and total cholesterol to
91.2%. α-tocotrienol treatment in human neuroblastoma cells resulted in an even more pronounced
reduction in unesterified cholesterol and total cholesterol to 63.7% and 57.7%, respectively. Notably, the
reduction of total cholesterol and unesterified cholesterol level in α-tocotrienol-treated cells was highly
significant compared to α-tocopherol, indicating that α-tocotrienol has with respect to cholesterol
and AD a more beneficial effect than α-tocopherol. In line with our study, Krycer et al. [46] reported
decreased SREBP-2 activity in the presence of 10 µM α-tocotrienol by degrading mature SREBP-2.
δ- and γ-tocotrienols were even more potent inhibitors of SREBP-2 than α-tocotrienol [46]. This trend
was also observed in the study by Song and DeBose-Boyd [44].
According to the cholesterol-lowering properties of tocopherols and tocotrienols, several studies
reported a lower risk of mild cognitive impairment (MCI) and AD in populations with elevated plasma
levels of tocopherols and tocotrienols [64–67]. High dietary intake of the combination of all natural
vitamin E congeners has been shown to exhibit protection against AD [68]. Dietary intake of mixed
tocotrienols in subjects with cardiovascular risk factors and white matter lesions (WMLs) also revealed
neuroprotective properties by reducing the progression of WMLs [69]. However, supplementing AD
patients with vitamin E showed no clear beneficial effect on disease progress [70–72]. Meta-analysis
of 135,967 participants in 19 clinical trials even revealed that high-doses (≥400 IU/d) of vitamin E
supplement may increase all-cause mortality [73]. Despite the observed cholesterol-lowering effect of
α-tocotrienol to approximately 60%, we found an increase of the Aβ level in α-tocotrienol APP695
transfected SH-SY5Y cells to 116.7%. Considering the cholesterol-lowering properties of α-tocotrienol,
one would expect that total Aβ level should decrease, as cholesterol has been shown to increase Aβ
level [17,18,20]. However, we found that α-tocotrienol has, besides the effect on cholesterol, a direct
increasing effect on the secretases activities, resulting in an increased Aβ production. Under the
conditions used in this study, the Aβ increasing effect of tocotrienol on the secretases was more
pronounced than the Aβ lowering effect of a reduced cholesterol level. However, we cannot rule out
that under different experimental conditions, the cholesterol lowering effect is the more dominant
effect on the Aβ level.
The total Aβ level is increased by the direct effect of α-tocotrienol on β- and γ-secretase
activity, as cell-free assays showed an increase in β-secretase activity to 116.3% and an elevation
to 118.3% for γ-secretase, whereas gene transcription and protein level of β-secretase BACE1 and the
components of the γ-secretase complex were unchanged. Besides directly affecting secretase activities,
we found that α-tocotrienol decreased Aβ degradation to 82.1%, also resulting in elevated Aβ level.
The inauspicious amyloidogenic potential of vitamin E molecules accompanied by a reduction in Aβ
degradation was already shown in our previous study for tocopherols [42]. However, as vitamin E
molecules exert different physiological activities, one cannot exclude that other indirect effects may
also contribute to an increase in the Aβ level. Although vitamin E molecules function as an antioxidant,
scavenging toxic free radicals discussed to contribute to the pathological processes of AD, one has
to take into consideration that elevated Aβ levels in presence of tocopherols and tocotrienols might
increase Aβ-induced oxidative stress [61,74]. Based on the multifaceted cellular mode of action of
vitamin E, one might speculate that some patients might profit from vitamin E supplementation,
but others not. For example, individuals with hypercholesterolemia might profit from vitamin E
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because of the cholesterol-lowering effect of vitamin E, whereas in individuals with normal or low
cholesterol, the amyloid potential of tocopherols and tocotrienols predominates. On the other hand,
individuals with a low plasma level of tocopherols and tocotrienols might also benefit from vitamin E
supplementation. Nishida et al. have shown that depletion of vitamin E by crossing AD transgenic
APP-Swedish mice with α-tocopherol transfer protein knock-out mice increased Aβ deposits in the
brain, which was ameliorated with α-tocopherol supplementation [75]. In line with these findings,
dietary supplementation with N-acetylcysteine, α-lipoic acid and α-tocopherol attenuated age-related
alterations in amyloid βmetabolism, an increase in APP, β-secretase activity and a decrease in the Aβ
degrading enzyme neprilysin, in aged rat brain [76] and prevented deficits in learning and memory
functions [77]. On the other hand, treating MCI/AD patients with vitamin E revealed no significant
differences in the rate of progression to AD between the vitamin E and placebo groups [70,71].
4. Materials and Methods
4.1. Chemicals
Chemicals including (+)-α-tocopherol and (+)-α-tocotrienol, as well as cell culture media were
purchased from Sigma (Taufkirchen, Germany) unless otherwise noted.
4.2. Cell Culture
SH-SY5Y wildtype (wt) cells were cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 10% fetal calf serum (FCS) (PAN Biotech, Aidenbach, Germany). For SH-SY5Y APP
(overexpressing the human APP695 isoform) and SH-SY5Y C99 cells (overexpressing the β-cleaved
C-terminal fragment) [78], Hygromycin B (PAN Biotech) was supplemented in a final concentration of
0.3 mg/mL.
Neuro 2a (N2a) cells were cultivated in DMEM comprising 10% FCS, 1% penicillin/streptomycin
solution, 2 mM L-glutamine, 0.1 mM MEM and 1 mM sodium-pyruvate.
Twelve hours before incubation, FCS in cell culture medium was reduced to 0.1%.
Tocopherol and tocotrienol (dissolved in ethanol) were incubated in a concentration of 10 µM in
0.1% FCS/DMEM for 24 h (8 + 16 h); controls were treated with the appropriate ethanol concentration
(1%). Depending on subsequent experiments, cells were either lysed chemically in lysis buffer
(0.1% NP-40, 0.1% Triton-X-100, 10 mM Tris, 2 mM EDTA) with or without protease inhibitor
(Roche Diagnostics, Mannheim, Germany) or homogenized mechanically using a Minilys homogenizer
(Peqlab, Erlangen, Germany).
4.3. Cell Viability
After incubation with tocopherol and tocotrienol, cell viability was identified by measuring lactate
dehydrogenase activity using the Cytotoxicity Detection KitPLUS (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions.
4.4. Cholesterol Concentration
After long-term incubation for five days (3 days with 1% FCS followed by treatment for 48 h
in 0.1% FCS) with 10 µM tocopherol and tocotrienol, cholesterol content in samples was measured
by using the Amplex Red Cholesterol Assay Kit (Invitrogen, Karlsruhe, Germany) according to the
manufacturer’s protocol.
4.5. Detection of Reactive Oxygen Species
To detect ROS with aminophenyl fluorescein, cells were incubated on 96-well plates and washed
once with prewarmed (37 ◦C) cell imaging solution (140 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, 1 mM
MgCl2, 20 mM HEPES, pH 7.4). On hundred microliters of aminophenyl fluorescein (Sigma Aldrich,
Taufkirchen, Germany) in a final concentration of 10 µM in cell imaging solution were added to each
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well. After incubation for 60 min in the dark at 37 ◦C, the plate was shaken for 60 s, and fluorescence was
measured with an excitation wavelength of 490 ± 10 nm and an emission wavelength of 515 ± 10 nm
using a Safire2 Fluorometer (Tecan, Crailsheim, Germany).
To evaluate the antioxidative potential of α-tocopherol and α-tocotrienol against hydrogen
peroxide, parts of the Amplex Red Cholesterol Assay Kit (Invitrogen) were used. Cells were incubated
on 96-well plates with the addition of 1 µM H2O2 and washed with warmed phosphate-buffered
saline. Fifty microliters 1× reaction buffer (0.1 M potassium phosphate, 50 mM NaCl, 5 mM cholic acid,
0.1% Triton X-100, pH 7.4) were added to each well, and the plate was sonificated for 10 s. Afterwards,
50 µL 1× reaction buffer containing 300 µM Amplex Red reagent and 2 U/mL horseradish peroxidase
were pipetted to each sample, and the plate was shaken for 60 s. Ten microliters of 10 µM H2O2 were
added to each well and mixed by shaking. The plate was incubated 40 min under light exclusion
at 37 ◦C, shaken for another 60 s, and fluorescence was measured with an excitation wavelength of
540 ± 10 nm and an emission wavelength of 590 ± 10 nm.
4.6. Determination of Protein Concentration
Protein concentration in samples was determined with bicinchoninic acid as described in [79].
Before conducting the experiments, samples were adjusted to equal protein concentrations.
4.7. Western Blot Analysis
The total protein concentration in samples was measured and equaled as mentioned above.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed with 10%–20%
Tricine gradient gels (Anamed, Groß-Bieberau, Germany). Afterwards, proteins were transferred onto
nitrocellulose membranes (Whatman, Dassel, Germany), and the following antibodies were used for
Western blot (WB) analysis: W02 antibody (5 µg/mL) (Millipore, Billerica, MA, USA), anti-BACE1
(B0806) (1:1000, Sigma), anti-nicastrin 1 (1:500, sc25648) (Santa Cruz, Dallas, TX, USA) and anti-sAPPβ
(1:250, MBS492139) (MyBioSource, San Diego, CA, USA) as primary antibodies; anti-rabbit (W401B)
(1:5000, Promega, Mannheim, Germany) and anti-mouse (P0260) (1:10,000, Dako, Hamburg, Germany)
as secondary antibodies.
Analysis of the Aβ protein level was performed as described earlier [80]. For detection in WB
analysis, Aβ was immunoprecipitated with 20 µL protein G-Sepharose (Sigma) and W02 antibody
(5 µg/mL). Aβ peptides were detected by the use of W02 in WB. The specificity, sensitivity and
linearity of this assay were validated in Ida et al. [80]. Previously, we additionally confirmed the
specificity, sensitivity and linearity of Aβ detection by using the W02 antibody under our experimental
conditions [81].
Proteins were detected by the enhanced chemiluminescense (ECL)-method (Perkin Elmer,
Rodgau-Jügesheim, Germany) and densitometrically quantified with Image Gauge V3.45 software
(Fujifilm, Düsseldorf, Germany).
4.8. Preparation of Purified Membranes
The preparation of purified membranes was conducted according to [82]: after washing three
times with precooled (4 ◦C) phosphate buffered saline (PBS), SH-SY5Y wt cells were scraped in sucrose
buffer (10 mM Tris/HCl, pH 7.4, 1 mM EDTA, 200 mM sucrose) and homogenized using a Minilys
homogenizer (Peqlab) at maximum speed for 30 s. Total protein amount was measured and equaled
as mentioned above. Samples were centrifuged at 900 relative centrifugal force (rcf) for 10 min at
4 ◦C; supernatants were collected in a new tube and centrifuged again (Optima MAX Ultracentrifuge,
Beckman Coulter, Krefeld, Germany) for 75 min at 55,000 rpm and 4 ◦C. Pellets were resuspended in
sucrose buffer at medium speed for 10 s using Minilys (Peqlab).
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4.9. Measurement of β- and γ-Secretase Activity
Evaluation of β- and γ-secretase activity has been described in detail earlier [20]. Shortly,
fluorogenic β-secretase substrate IV (Calbiochem, Darmstadt, Germany) or γ-secretase substrate
(Calbiochem) was added in a final concentration of 20 or 10 µM to samples, respectively. In the
case of β-secretase, the resulting fluorescence was measured continuously under light exclusion with
a Safire2 Fluorometer (Tecan) at an excitation wavelength of 345± 5 nm and an emission wavelength of
500 ± 2.5 nm, for γ-secretase at an excitation wavelength of 355 ± 10 nm and an emission wavelength
of 440 ± 10 nm.
4.10. Measurement of Secretase Activity in Living Cells
SH-SY5Y wt cells were incubated with tocopherol and tocotrienol and washed with prewarmed
cell imaging solution (140 mM NaCl, 5 mM KCl, 8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, pH 7.4).
Thirty micromolar fluorogenic β-secretase substrate (Calbiochem) or 12 µM γ-secretase substrate
(Calbiochem) in 50 µL of cell imaging solution was added, and fluorescence was determined under
light exclusion at 37 ◦C in a Safire2 Fluorometer (Tecan) with excitation wavelengths of 345 ± 5 nm
and 355 ± 10 nm and emission wavelengths of 500 ± 2.5 and 440 ± 10 nm, respectively [42].
4.11. Quantitative Real-Time Experiments
SH-SY5Y wt cells were incubated as mentioned above and TRIzol reagent (Invitrogen) was used
to isolate total RNA, of which 2 µg were used in reverse transcription with the High-Capacity cDNA
Reverse Transcription Kit (Life Technologies, Darmstadt, Germany). Fast SYBR Green Master Mix
(Applied Biosystems, Darmstadt, Germany) was utilized for quantitative real-time polymerase chain
reaction on a Piko Real-Time PCR System (Thermo Scientific, Waltham, MA, USA). Experiments were
carried out according to the manufacturers’ protocols. Data evaluation and primer sequences are
described in detail in [42].
4.12. Determination of Total Aβ Degradation
Evaluation of Aβ degradation has been described earlier [42]. Before incubation, N2a wt cells
were cultivated for 6 h with reduced FCS (0.1%). Subsequently, tocopherol and tocotrienol (10 µM)
were applied to the cells for 18 h followed by an additional treatment for 6 h with tocopherol and
tocotrienol in combination with 0.5 µg/mL human synthetic Aβ40. To inhibit the activity of IDE [83],
cells were additionally incubated with 10 µM human insulin (Sigma). Non-degraded human Aβ40
from cell culture supernatant was separated in SDS-PAGE and detected by Western blotting using the
W02 antibody as described above.
4.13. Tocopherol and Tocotrienol Uptake
For quantification of α-tocopherol and α-tocotrienol in control samples, we pooled 5 independent
control samples. The standard addition method with 0.02, 0.05, 0.1, 0.2, 1 and 2 nmol/mg protein
of α-tocopherol and α-tocotrienol was used to calculate calibration curves (R2 > 0.97). The resulting
control sample concentration of α-tocopherol was 0.067± 0.031 nmol/mg protein and for α-tocotrienol
0.034 ± 0.005 nmol/mg protein.
Tocopherols and tocotrienols were significantly (>500%, p ≤ 0.001) taken up by cells. Analyses
were performed by mass spectrometry (see below): isotopically-labeled (±)d6-α-tocopherol,
HPLC-grade ethyl acetate and HPLC-MS-grade acetonitrile were purchased from Sigma-Aldrich
(Steinheim, Germany); 2,6-di-tert-butyl-4-methylphenol (butylhydroxytoluene, BHT) from Merck
Schuchardt OHG (Hohenbrunn, Germany); ascorbic acid and sodium hydroxide from Carl Roth
GmbH (Karlsruhe, Germany); HPLC-grade dichloromethane and HPLC-grade water from VWR
International (Darmstadt, Germany); analytical reagent grade n-hexane from Fischer Scientific UK
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(Loughboroug, UK); sodium hydroxide and 37% hydrochloric acid from Merck (Darmstadt, Germany);
and formic acid from AppliChem (Darmstadt, Germany).
4.13.1. Sample Preparation
For extraction, we used saponification combined with liquid/liquid extraction. This combination
is widely used in the literature to extract tocopherols from biological samples [48,84].
All extractions were carried out in triplicate from three independent 10-cm culture dishes, which
were incubated for 24 h (8 + 16 h), as described before with 10 µM α-tocopherol, 10 µM α-tocotrienol
and ethanol as the control.
Prior to extraction, the culture medium was removed; cells were washed three times with 1 mL
of water and dissolved in 200 µL of water. The cells were homogenized using glass beads in Minilys
(Peqlab) for 30 s at maximum speed and diluted to a protein concentration of 10 mg/mL.
The following solvents were used for extraction: (A) internal standard solution of 20 µM
d6-α-tocopherol and 0.1% (w/w) BHT in acetonitrile; (B) 1.14 M ascorbic acid and 1.14 M sodium
hydroxide in water/methanol 2:1 (v/v); (C) 10 M sodium hydroxide in water/methanol 2:1
(v/v); (D) 3.2 M hydrochloric acid in water/acetonitrile 2:3 (v/v); and (E) extraction solution
dichloromethane/ethyl acetate/n-hexane 6:1:1 (v/v). For extraction, 30 µL of the homogenized
cell sample at a 10-mg/mL protein concentration were mixed with 15 µL internal standard solution (A);
20 µL of solution (B) and 20 µL of solution (C) were added and the mixture saponificated at 55 ◦C under
horizontal shaking conditions at 800 rpm for 20 min (Eppendorf Thermomixer, Hamburg, Germany).
This was followed by cooling on ice, adding 60 µL of solution (D) and 330 µL of extraction solution (E).
To achieve extraction equilibrium, the mixture was shaken for 20 min at 400 rpm, the organic layer
removed, dried under a gentle stream of nitrogen and the residue dissolved in 200 µL of acetonitrile.
4.13.2. LC-MS/MS
For LC-MS/MS analysis, 1 µL of the extract was injected into an Agilent (Santa Clara, CA, USA)
1200 Series capillary HPLC system. An Agilent Zorbax SB-C18 column was used for separation at
a 20 µL/min isocratic flow rate of 100% acetonitrile (+0.1% formic acid). The column temperature
was set to 25 ◦C in a MayLab (Vienna, Austria) Mistra-Switch column oven. Retention times under
these conditions were 1.9 min for α-tocotrienol and 4.5 min for tocopherol. Detection of α-tocotrienol
and α-tocopherol was achieved on a Sciex (Concord, ON, Canada) QTRAP 4000 triple quadrupole
mass spectrometer in positive electrospray ionization (ESI) mode using selected reaction monitoring
(SRM). The MS conditions were as follows: spray voltage, 5500 V; source temperature, 120 ◦C; curtain
gas, 27 psi; Gas 1, 25 psi; Gas 2, 25 psi; entrance potential, 10 V; collision exit potential, 14 V; interface
heater, on; declustering potential (DP) and collision energy (CE), compound specific. SRM-transition
was m/z 423.3→ 165.1 for α-tocotrienol (CE = 27 V, DP = 55 V); m/z 429.4→ 165.1 for α-tocopherol
(CE = 33 V, DP = 80 V); and m/z 435.4→ 171.1 for d6-α-tocopherol (CE = 33 V, DP = 80 V). For all
SRM transitions, dwell-times were 200 ms. Under ESI conditions, the formation of [M − H]+ ions after
hydride abstraction from the analyte molecules was unusual; however, a similar behavior was reported
for tocopherol under atmospheric pressure chemical ionization (APCI) conditions [85]. This ion was
used as the precursor ion for SRM, as it formed the base peak in the collision-induced dissociation
(CID) spectra under the described conditions.
4.14. Statistical Analysis
Data are illustrated as an average of at least three independent experiments, instead of; the exact
n-number for each experiment is listed in the figure legend. Error bars show the standard deviation of
the mean. A two-tailed Student’s t-test was used for calculating statistical significance, which was set
at * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. For multiple comparison analysis of the different vitamin E
species, post hoc ANOVA was conducted.
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5. Conclusions
In summary, we could show that α-tocopherol and α-tocotrienol showed a nearly identical
beneficial effect regarding the formation of ROS, whereas α-tocotrienol revealed an even more
pronounced effect in the reduction of cholesterol level. Both, reduced ROS/lipid peroxidation and
reduced cholesterol level are beneficial for AD (Figure 4). However, α-tocotrienol and tocopherols
increase the release of Aβ by increased amyloidogenic APP processing and decrease the degradation
of Aβ leading to the formation of neuritic plaques. Indisputable positive effects, but also negative
modes of action of the vitamin E family with respect to the mechanisms involved in AD pathogenesis
have to be taken into consideration when deciding whether patients could benefit from vitamin E
supplementation or not.
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